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Previous research has shown that a single dose of MDMA induce a dissociative state,
by elevating feelings of depersonalization and derealization. Typically, it is assumed
that action on the 5-HT2A receptor is the mechanism underlying these psychedelic
experiences. In addition, other studies have shown associations between dissociative
states and biological parameters (heart rate, cortisol), which are elevated by MDMA. In
order to investigate the role of the 5-HT2 receptor in the MDMA-induced dissociative
state and the association with biological parameters, a placebo-controlled within-
subject study was conducted including a single oral dose of MDMA (75 mg), combined
with placebo or a single oral dose of the 5-HT2 receptor blocker ketanserin (40 mg).
Twenty healthy recreational MDMA users filled out a dissociative states scale (CADSS)
90 min after treatments, which was preceded and followed by assessment of a number
of biological parameters (cortisol levels, heart rate, MDMA blood concentrations).
Findings showed that MDMA induced a dissociative state but this effect was not
counteracted by pre-treatment with ketanserin. Heart rate was the only biological
parameter that correlated with the MDMA-induced dissociative state, but an absence of
correlation between these measures when participants were pretreated with ketanserin
suggests an absence of directional effects of heart rate on dissociative state. It is
suggested that the 5-HT2 receptor does not mediate the dissociative effects caused by
a single dose of MDMA. Further research is needed to determine the exact neurobiology
underlying this effect and whether these effects contribute to the therapeutic potential
of MDMA.
Keywords: MDMA, dissociative state, cortisol, heart rate, 5-HT2 receptor, MDMA concentration,
depersonalization, derealization
INTRODUCTION
Classical psychedelics like lysergic acid diethylamide (LSD), N,N-Dimethyltryptamine (DMT) and
psilocybin are known for their mind-altering and dissociative states, as well as the spiritual or
mystical-like experience often reported by users (Goodman, 2002; Trichter et al., 2009; Griffiths
et al., 2011). These dissociative experiences, characterized by a disruption of cognitive and motor
processes, can be viewed as a continuum ranging from excessive daydreaming and memory
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problems to more severe forms of depersonalization or
derealization disorders (Association, 2013). Previously, it has
been shown that a single dose of MDMA can also acutely
induce a dissociative state, as measured with the Altered
States of Consciousness Scale and the Clinician-Administered
Dissociative State Scale (CADSS) (Vollenweider et al., 1998; van
Heugten-Van der Kloet et al., 2015). It was found to exceed
the non-psychotic state of schizophrenic patients, yet to be
milder than the dissociative state induced by a typical psychedelic
(psilocybin) or a dissociative (ketamine), and to be experienced
as non-problematic by the psychedelic user (Vollenweider et al.,
1998; Jansen, 2000; van Heugten-Van der Kloet et al., 2015). This
effect has been shown to be dose-dependent, i.e., whereas low
doses of MDMA (25–50 mg) did not induce a dissociative state,
a higher dose (100 mg) did, 90 min after administration (van
Heugten-Van der Kloet et al., 2015).
It is generally assumed that the hallucinogenic actions of
classical psychedelics arise from their action on the serotonin
2A (5-HT2A) receptor (Glennon et al., 1984; Vollenweider
and Kometer, 2010). Likewise, studies have demonstrated
that 5-HT2A receptors mediate MDMA-induced alterations
in mood and perception (Liechti et al., 2000; van Wel et al.,
2012). Specifically, pre-treatment with the 5-HT2 antagonist
ketanserin selectively reduced MDMA-induced perceptual
changes, emotional excitation, and alterations in positive affect
(Liechti et al., 2000, 2001; Liechti and Vollenweider, 2001;
van Wel et al., 2012). Based on this it was hypothesized that
the 5-HT2 receptor could play a role in the MDMA-induced
dissociative symptoms.
In addition, studies have demonstrated relationships between
specific biological parameters like cortisol levels and heart
rate, and state and/or trait dissociation in healthy and patient
populations (Giesbrecht et al., 2007; Simeon et al., 2007).
Previous studies have for example suggested a blunting of the
autonomic responses, i.e., heart rate, skin conductance, and
(nor)epinephrine levels, to stressful traumatic stimuli in acute
dissociative states (Griffin et al., 1997; Delahanty et al., 2003).
One study even showed an inverse relationship between cortisol
stress reactivity and dissociation in dissociative disorder patients
and post-traumatic stress disorder patients (Simeon et al., 2007).
In healthy participants the cortisol response to a psychological
stressor was shown to correlate positively with trait dissociation
as measured with the depersonalization-derealization subscale
of the Dissociative Experiences Scale (DES). Participants with
the highest scores on dissociation also had the largest cortisol
response to a stressor (Giesbrecht et al., 2007). In all these
studies the stressor was psychological by nature, i.e., real-life
events or stimuli, or laboratory procedures, causing the exposed
person to experience psychological stress. It is also known that
psychedelics, dissociatives, and MDMA produce a robust acute
increase the body’s stress system, e.g., causing an elevation in
cortisol levels and in cardiovascular parameters, making those
substances to be categorized as ‘biological’ stressors (White and
Ryan, 1996; Harris et al., 2002; Hasler et al., 2004; Parrott,
2009; Kuypers et al., 2013; van Heugten-Van der Kloet et al.,
2015). Given this information, it would be relevant to study
the association between these biological correlates of stress
and MDMA-induced dissociation. In addition, since previous
studies have shown MDMA concentrations in blood to correlate
positively with the MDMA-induced changes in behavioral
measures (e.g., emotional empathy and prospective memory)
(Ramaekers et al., 2009; Kuypers et al., 2017), it would be relevant
to explore the relation between MDMA concentrations and the
dissociative state.
In order to study the effects of the 5-HT2 receptor in
the MDMA-induced dissociative state, and the relationship to
cortisol levels, heart rate, and MDMA concentrations, a placebo-
controlled experimental study was set up including pretreatment
with ketanserin, a 5-HT2A blocker, and treatment with a single
dose of MDMA (75 mg). It was hypothesized that MDMA would




Participants were 20 healthy (12 males and 8 females) recreational
poly-drug users with a mean age of 21.2 years (SD: 2.6), who had
previously used ecstasy/MDMA with an average of 16.8 times
(SD: 23.2) during their lifetime. They were recruited through
advertisements at Maastricht University, a website (digi-prik.nl)
and by word-of-mouth.
Design and Treatments
The study was conducted according to a two by two double-
blind placebo-controlled within-subjects design. Pre-treatment
consisted of ketanserin (40 mg), which represents a regular
therapeutic dose that blocks 91% of 5-HT2 receptors (Brogden
and Sorkin, 1990; Sharpley et al., 1994), or placebo; Treatment
consisted of MDMA (75 mg) or placebo. Pre-treatment and
treatment were administered orally in identically appearing
capsules using a double-blind, placebo-controlled, double-
dummy procedure. A double-dummy procedure was used to
control for differences in Tmax between both drugs. Tmax of
MDMA is 2 h (de la Torre et al., 2004), Tmax of ketanserin is
between 0.5 and 4 h (Reimann et al., 1983; Heykants et al., 1986;
Persson et al., 1991). The timing and doses of the (pre-)treatment
were based on similar research by the same group (van Wel et al.,
2011, 2012) were it was shown -amongst other- that the MDMA-
induced elevated mood state was blocked by ketanserin (50 mg)
(van Wel et al., 2012).
A permit for obtaining, storing, and administering MDMA
was obtained from the Dutch drug enforcement administration.
Randomization of pre-treatment and treatment conditions was
generated by means of a Latin Square, with each subject being
assigned to a treatment sequence.
Procedure
Prior to participation all participants were medically assessed
by a physician, who examined general health (including an
ECG) and took blood and urine samples for standard chemistry
and hematology. In addition, they were familiarized with the
procedures, tests and questionnaires on a training day, and
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a questionnaire assessing dissociative trait was administered,
preceding actual test days. Participants were requested to abstain
from any drug use 1 week before the medical examination until
the last test day. They were asked not to use any caffeinated or
alcoholic beverages 24 h before testing and to get a normal night’s
sleep.
Participants were screened for recent drug consumption
in urine (THC, opiates, cocaine, amphetamine/ecstasy, and
benzodiazepines) and alcohol in breath upon arrival (9 AM) on
test days. In addition, women were given a pregnancy test. When
tests were negative, participants had breakfast and filled out a
questionnaire assessing baseline dissociative symptoms (CADSS),
and blood samples were collected. At 9:30 AM participants
received pre-treatment followed half an hour later by treatment.
Participants were then seated in a waiting room for 90 min
after which a second blood sample was taken and the CADSS
was filled out again. The test day ended with a measurement of
cardiovascular parameters and a third blood sample, at 12:30 PM,
150 min after treatment, 180 min after pre-treatment.
The procedure entailed four test sessions on four separate
days, with a minimum of 7 days between test days as washout
period. Participants provided written informed consent to
participate in this study and were paid upon completion of
the testing periods for their participation. The study was
performed in accordance with the Helsinki Declaration of
1975 and its amendments, and was approved by the Medical
Ethics Committee of the Academic Hospital of Maastricht and
Maastricht University.
Dissociative Trait and State Measures
Dissociative Experiences Scale
The DES is widely acknowledged as a standard instrument
for trait dissociation. It comprises 28 items that assess the
frequency of various dissociative phenomena in daily life.
Participants indicate on 100-mm visual analog scales (anchors:
0 = not at all; 100 = very much) the percentage of time that
they have experienced phenomena like talking out loud to
oneself when one is alone or not recognizing friends or family
members. The scale consists of five subscales, i.e., ‘Amnestic,’
‘Absorption/Imagination,’ ‘Depersonalization/Derealization,’
‘Absorption/Changeability,’ ‘Taxon DES scale.’ The latter scale
provides a clinical mean cut-off score (cut-off score ≥ 20)
suggesting further clinical assessment (Thomson and Jaque,
2012). To obtain a mean DES score, scores are averaged
across items. Higher scores indicate a higher frequency
of dissociative symptoms reported by the participant
(Merckelbach et al., 2002).
Clinician-Administered Dissociative States Scale
The CADSS is an instrument developed for the measurement
of present-state dissociative symptoms. The scale consists of a
19 self-report items and 8 observation items. The intensity of
each dissociative symptoms ranges from 0 (not present at all)
to 4 (extremely present). Respondents were instructed to use
their current state (up too last 3 h) as a point of reference
when completing items. We only employed the self-report items
(1–19), and by summing across items we calculated a total
score (0–76) and three subscales of ‘depersonalization’ (0–20),
‘derealization’ (0–48), and ‘amnesia’ (0–4).
Biological Correlates of Stress and
Pharmacokinetics
Heart rate and blood pressure (diastolic and systolic) were
assessed three times during a test day followed each time by blood
drawing, i.e., at baseline, pre-test, and post-test. Blood samples
were collected in order to determine, MDMA and ketanserin.
Cortisol Concentrations
A 2-ml sample for cortisol analysis was drawn and collected in
EDTA tubes. Samples were immediately centrifuged at 3000 rpm
for 10 min at 4◦C. Plasma was removed and frozen at −20◦C
until analysis. Cortisol samples were analyzed with the DPC
IMMULITE 1000 R© chemoluminescence immunoassay analyser
(Siemens Healthcare Diagnostics).
Pharmacokinetics
Samples were centrifuged immediately and resulting plasma
was stored at −20◦C until analysis. MDMA, were determined
by gas-chromatography coupled to mass spectrometry using a
method previously described by Pizarro et al. (2002). Ketanserin
was determined by liquid chromatography coupled to mass
spectrometry. Samples (200 µL of plasma) were purified with
Ostro Pass-through Sample Preparation Plates (Waters, Beverly,
MA, United States) and 600 µL of acetonitrile with 0.1%
formic acid was used as the elution solvent. After mixing,
vacuum was applied and the collected mixture was evaporated
to dryness at 15 psi and 40◦C. Extract was reconstituted with
100 µL of ammonium formate 0.02% at pH 5 and acetonitrile
(50: 50 v/v). Quantification was performed in an HPLC system
coupled to a triple-quadrupole (6410 Triple Quad LC-MS;
Agilent) mass spectrometer with an electrospray interface. The
chromatographic separation was done using a C18 column
(Kinetex, 100 mm × 3 mm × 1.7 µm, Phenomenex, Torrance,
CA, United States). The mobile phase was ammonium formate
0.02% at pH 5 and acetonitrile in an isocratic mode (50: 50 v/v)
at a flow rate of 0.45 mL/min. All compounds were monitored in
positive ionization using the multiple reaction mode Mass/charge
(M + 1/z) values selected for identification of analytes were
as follows: ketanserin 396→146, 189, 208 and pirenperone
394→119, 159, 187, fragmentor (F) 200 V, collision energy (CE).
Statistical Analysis
Clinician-Administered Dissociative State Scale data entered a
general linear model (GLM), repeated measures procedure (SPSS,
version 24.0) with Pre-treatment (two levels: ketanserin, placebo)
and Treatment (two levels: MDMA, placebo) as main within
subject factors.
For the cardiovascular parameters and cortisol concentrations,
baseline measures were collected. First, a GLM was conducted,
including only baseline to test for baseline differences. In
case there were no differences, another GLM was conducted,
including only the second (pre-test) or third (post-test) measure.
To study whether ketanserin and MDMA plasma
concentrations differed significantly between conditions in
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FIGURE 1 | Mean (± SE) ratings on the subscales (A) Derealization, (B) Depersonalization, (C) Amnesia of the CADSS and the sum score (D) of the scales, during
baseline and 120 and 90 min after pre-treatment and treatment respectively.
which ketanserin or MDMA were administered alone or
together, separated by 30 min, paired sample t-tests were
conducted.
Pearson’s correlations were calculated in order to explore
potential relationships between cardiovascular parameters and
cortisol concentrations, and between these measures and
measures of dissociation (DES, CADSS) and between MDMA
concentrations and measures of dissociative state (CADSS).
Pearson’s correlations were only conducted on the second
measurement, which coincided with the assessment of the
dissociative state.
The alpha criterion level of statistical significance for all
analyses was set at p = 0.05; partial eta2 (η2) is reported in case
of significant effects to demonstrate the effect’s magnitude (0.01:
small, 0.06: moderate; 0.14: large).
RESULTS
Dissociative Trait and State Measures
Dissociative Experiences Scale
Participants had a mean (± SE) total DES score of 13.8 (2.8). This
score is in the range previously reported in healthy participants
(Merckelbach et al., 2002). Mean scores for the DES-T, Amnesia,
Absorption/Imagination, Depersonalization/Derealization, and
Absorption/Changeability were 5.6 (2.2), 10.3 (2.9), 17.6 (3.9), 2.7
(1.6), and 16.6 (3.6), respectively.
Clinician-Administrated Dissociative States Scale
Analyses revealed a main effect of Treatment (MDMA) on the
three CADSS subscales, i.e., Depersonalization, Derealization,
and Amnesia (F1,19 = 11.62, p = 0.003; η2 = 0.38). MDMA
induced an increase in the ratings on these scales compared
to placebo. There was a main effect of Scales (F2,38 = 10.02,
p < 0.001; η2 = 0.34) indicating significant differences between
Derealization and both Depersonalization and Amnesia. The
ratings on the latter scales were lower compared to the
former scale. There was also a Treatment by Scale interaction
(F2,38 = 10.97, p< 0.001; η2 = 0.37) indicating that the influence
of MDMA on the Derealization rating was more pronounced
than on the ratings of Depersonalization and Amnesia. There
was no significant Pretreatment (ketanserin) by Treatment
interaction effect, i.e., ketanserin did not change the effects of
MDMA on dissociative experiences (Figure 1). There were no
differences on baseline CADSS ratings between conditions.
Biological Correlates of Stress and
Pharmacokinetics
Cardiovascular Parameters
Baseline cardiovascular parameters did not reveal statistically
significant differences between conditions. Mean (± SE) blood
pressure (BP) and heart rate (HR) values were: 123.4± 1.8 mmHg
for systolic BP, 71.6 ± 1.4 mmHg for diastolic BP, and
74.3± 1.5 bpm for HR.
Analysis including the second (i.e., pre-test) measurement
revealed a main effect of Treatment on blood pressure and
heart rate. Under influence of MDMA blood pressure and heart
rate were elevated compared to placebo; respective differences
were 12.5 mmHg (systolic BP), 6.2 mmHg (diastolic BP), and
10.4 bpm (HR).
Analysis including the third (i.e., post-test) measurement
revealed main effects of Pre-treatment and Treatment on blood
pressure and heart rate and an interaction effect on heart
rate. The Treatment effect indicated an elevating influence of
MDMA on blood pressure and heart rate; differences from
placebo were respectively 10.9 mmHg (systolic BP), 8.2 mmHg
(diastolic BP), and 13.2 bpm (HR). The Pre-treatment effect
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pointed to a reducing influence of ketanserin on blood pressure
and heart rate; differences from placebo were respectively
7.8 mmHg (systolic BP), 6.1 mmHg (diastolic BP), and
3.4 bmp (HR). The Pre-treatment by Treatment interaction
effect indicated that ketanserin partially counteracted the
MDMA-induced increase in heart rate, i.e., heart rate was still
higher in the combined condition but was lower than the
MDMA only condition and still higher compared to placebo
(Table 1).
Cortisol Concentrations
Analyses revealed no differences in baseline cortisol serum
concentrations (nmol/L). There was a main effect of Treatment
on cortisol levels 90 (F1,10 = 9.70, p = 0.01; η2 = 0.49)
and 150 (F1,11 = 65.67, p < 0.001; η2 = 0.86) minutes
after administration. MDMA caused an elevation of cortisol
concentrations compared to placebo, i.e., concentrations were 1.6
times higher after MDMA administration compared to placebo.
Analyses revealed a main effect of Pre-treatment (F1,11 = 57.23,
p < 0.001; η2 = 0.84) and a Pre-treatment by Treatment
interaction effect (F1,11 = 40.49, p< 0.001; η2 = 0.79) on cortisol
concentrations, 150 min after treatment and 180 min after pre-
treatment administration respectively showing a counteraction
of the MDMA-induced cortisol increase. When MDMA was
combined with ketanserin, cortisol concentrations dropped with
a factor of 1.9 compared to the MDMA only condition, but they
were still 1.4 times higher compared to the placebo condition
(Figure 2).
There was no effect of Pre-treatment or a Pre-treatment
by Treatment interaction on cortisol levels 90 min after
administration of treatment, respectively 120 min after pre-
treatment.
Pharmacokinetics: MDMA and Ketanserin
Concentrations
Paired sample t-tests showed that MDMA plasma concentrations
(ng/mL) did not statistically differ between the MDMA alone
condition [mean (± SE): 90′ post-MDMA: 134. 8 (16.6); 150′
post-MDMA: 186.0 (17.7)] and the condition where it was
combined with ketanserin [mean (± SE): 90′ post-MDMA:
126.7 (15.1); 150′ post-MDMA: 182.9 (14.7)]. The same was
shown for ketanserin plasma concentrations (ng/mL) that did not
differ between the ketanserin alone condition [mean (± SE): 90′
post-MDMA: 54.9 (7.6); 150′ post-MDMA: 64.5 (6.0)] and the
condition where it was combined with MDMA [mean (± SE): 90′
post-MDMA: 59.0 (8.8); 150′ post-MDMA: 61.5 (5.4)].
Correlational Analyses
State and Trait Dissociative Experience
Trait dissociation as measured with the DES did not correlate
with state dissociation as measured with the CADSS, i.e.,
Pearson’s correlations between DES-T and CADSS-Total ranged
between −0.15 and 0.34, and correlations between DES-Total
and CADSS-Total ranged between −0.07 and 0.30 for the four
conditions.
Biological Correlates of the Dissociative State
Heart rate and cortisol levels
Analyses showed that heart rate and cortisol levels only correlated
significantly in the MDMA-alone condition (r15 = 0.69;
p = 0.005), 90 min after MDMA administration. Pearson’s
correlations in the other conditions were not significant and
ranged between−0.08 and 0.20.
Heart rate and cortisol levels did not correlate significantly
150 min after MDMA administration; correlations ranged
between−0.28 and 0.44.
Cortisol levels and the dissociative state
Cortisol levels only correlated significantly with scores on the
Amnesia subscale of the CADSS in the ketanserin only condition
(r19 = 0.68; p = 0.001) and the placebo condition (r18 = 0.49;
p= 0.04). Pearson’s correlations between cortisol levels and other
subscales of the CADSS and the total score of the CADSS in
the different conditions were not significant and ranged between
−0.14 and 0.51.
TABLE 1 | Mean (± SE) and general linear model (GLM) outcomes of the physiological measures, heart rate (HR) and blood pressure (BP); M = measurement;
1 = baseline; 2 = before cognitive tests (peak drug); 3 = after cognitive tests (end of test day); PT = pre-treatment; T = treatment; SBP = systolic blood pressure;
DBP = diastolic blood pressure.
GLM









F p F p F p
SBP 1 122.2 (3.3) 123.4 (3.4) 126.3 (4.1) 121.6 (4.0) 0.14 – 0.43 – 1.52 –
2 120.8 (3.0) 136.2 (4.4) 122.6 (3.6) 132.3 (4.1) 0.15 – 27.39 0.00 0.80 –
3 120.6 (3.3) 133.5 (2.6) 114.7 (3.3) 123.7 (3.7) 14.83 0.001 17.64 0.00 1.36 –
DBP 1 70.7 (2.2) 70.7 (2.0) 74.5 (3.8) 70.5 (2.8) 0.43 – 0.51 – 1.57 –
2 69.9 (1.7) 75.5 (2.3) 70.7 (2.7) 77.4 (2.7) 0.44 – 12.60 0.002 0.07 –
3 71.5 (1.8) 79.9 (2.5) 65.5 (1.7) 73.6 (2.5) 16.34 0.001 16.04 0.001 0.01 –
Heart rate 1 72.3 (2.6) 74.7 (3.4) 76.3 (3.1) 74.0 (3.3) 0.65 – 0.001 – 1.90 –
2 69.3 (3.2) 81.9 (3.7) 72.7 (2.3) 80.9 (4.1) 0.27 – 16.37 0.001 0.73 –
3 62.6 (1.7) 80.7 (2.8) 64.1 (2.4) 72.4 (2.7) 5.04 0.04 71.72 0.001 8.95 0.008
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Heart rate and the dissociative state
Heart rate correlated significantly with two subscales of the
CADSS, i.e., Derealization (r20 = 0.62; p = 0.004) and Amnesia
(r20 = 0.52; p = 0.02) and the total CADDS score (r20 = 0.60;
p = 0.001) in the MDMA condition. The other Pearson’s
correlations between heart rate and scales of the CADSS were not
significant and ranged between−0.23 and 0.37.
MDMA concentrations and the dissociative state
Correlation analyses revealed only one significant association
between MDMA concentrations in blood and dissociative state,
i.e., MDMA concentrations in the combined ketanserin and
MDMA condition correlated positively with the total score on the
CADSS (r18 = 0.47; p= 0.05).
Dissociative traits, state, and the MDMA-related cortisol
response
Since the cortisol response to a psychological stressor
was previously shown to correlate positively with the
depersonalization-derealization subscales of the DES (Giesbrecht
et al., 2007) this association was also assessed in the present
study. Cortisol response was defined as the percent change in the
MDMA condition from placebo [((cortisol concentrations
MDMA condition – cortisol concentrations Placebo
condition)/cortisol concentrations Placebo condition)∗100].
The ‘cortisol response’ score was calculated separately for
the MDMA condition in which ketanserin preceded MDMA
treatment and in which placebo preceded MDMA treatment.
Both scores were correlated with dissociative state and trait
measures.
Trait depersonalization and derealization as measured with
a subscale of the DES did not correlate significantly with the
cortisol response in the MDMA conditions (r14 = −0.32 in
the MDMA alone condition, and r15 = −0.17 in the combined
ketanserin-MDMA condition).
State dissociation as measured with the subscales of the
CADSS in the two MDMA conditions did not significantly
correlate with the cortisol response in the MDMA conditions
(range of r in MDMA alone condition = [−0.04 and 0.27];
ketanserin plus MDMA condition= [−0.22 and−0.13]).
DISCUSSION
The goal of this study was to investigate the role of the 5-
HT2A receptor in the MDMA-induced dissociative state and
to examine whether biological measures such as heart rate,
cortisol levels, and MDMA concentrations were correlated with
this dissociative state. It was shown that a single dose of
MDMA induced dissociative symptoms, i.e., 90 min after MDMA
administration ratings of depersonalization, derealization, and
amnesia were elevated. These effects were most pronounced
for the derealization scale and they were not changed by
ketanserin pre-treatment. MDMA caused an elevation of cortisol
levels and heart rate 90 min after administration and these
effects were partially counteracted by ketanserin, 150 min
after MDMA administration. Correlational analyses between
biological measures and the MDMA-induced dissociative state
FIGURE 2 | Mean (± SE) plasma concentrations of cortisol in the four
treatment conditions, at baseline, before tests (i.e., 90 min after treatment,
respectively 120 min after pre-treatment), and after tests (i.e., 150 min after
treatment, respectively 180 min after pre-treatment).
showed that heart rate was statistically significant related to these
MDMA effects while MDMA and cortisol concentrations were
not.
The effect of MDMA on dissociative symptoms replicates
findings from previous research and extends these. While it was
previously shown that lower single doses of MDMA (25–50 mg)
did not induce a dissociative state and a higher dose (100 mg)
did (van Heugten-Van der Kloet et al., 2015), it is now
demonstrated that 75 mg of MDMA also induces a dissociative
state. In line with previous research, ratings of derealization
were elevated after MDMA administration (van Heugten-Van
der Kloet et al., 2015), but in addition, 75 mg of MDMA also
increased ratings of Depersonalization and Amnesia. The absence
of an interaction between ketanserin and MDMA suggests a lack
of involvement of the 5-HT2A receptors in the MDMA-induced
dissociative state effects. This notion is supported by the finding
that MDMA-induced increases in ‘Oceanic Boundlessness,’ a
subscale of the Altered State of Consciousness measuring
derealization and depersonalization were not reduced by pre-
treatment with ketanserin (50 mg) (Liechti and Vollenweider,
2001). Our biological measures show, however, that 60 min after
CADSS completion, i.e., 150 min after MDMA administration,
respectively 180 min after ketanserin administration, MDMA-
induced elevations in cardiovascular parameters and cortisol
levels were attenuated or even counteracted by ketanserin. This
suggests that we should have measured dissociative symptoms a
third time, coinciding the biological change. Conversely, Liechti
and Vollenweider (2001) showing the same pattern on biological
parameters did not demonstrate changes in subjective effects
120 min after MDMA administration, respectively 195 min after
ketanserin administration. In addition, other stimulant drugs like
cocaine and mephedrone are known to produce similar biological
states without inducing dissociative states (Farré et al., 1997;
Papaseit et al., 2016). Together these findings support dissociation
between physiological and subjective effects, i.e., indicating that
MDMA effects on physiological parameters are mediated -
amongst other- by 5-HT2A receptors and the dissociative state is
not. However, future research should include multiple repetitions
Frontiers in Pharmacology | www.frontiersin.org 6 July 2017 | Volume 8 | Article 455
fphar-08-00455 July 11, 2017 Time: 12:7 # 7
Puxty et al. MDMA and the Dissociative State
of the CADSS to exclude the possibility that dissociative effects
are mediated by the 5-HT2A receptor at later moments in time.
Additionally, if the 5-HT2A receptor does not mediate this
MDMA-induced dissociative state, the question is still open
about which biological mechanism underlies this effect. In
trauma-related disorders it has been shown that heightened
glutamatergic neurotransmission occurs after stress exposure
and this is related to the manifestation of dissociative states
(Chambers et al., 1999). In addition, the increase in glutamate
levels, caused by the NMDA receptor antagonist ketamine, has
been shown to positively correlate with the degree of positive
psychotic symptoms (Stone et al., 2012). From preclinical work
it is known that MDMA causes an increase in glutamate
levels, however, it is supposed to be caused indirectly via
serotonergic stimulation of the 5-HT2A/C receptor (Anneken and
Gudelsky, 2012; Anneken et al., 2013). Experimental placebo-
controlled human MDMA studies including proton magnetic
resonance spectroscopy (1H-MRS) to assess brain glutamate
concentrations together with measures of dissociative state would
be a good starting point to confirm a relation between the
MDMA-induced dissociative state and glutamate concentrations
in the brain. These studies could be followed by dose-response
blockade studies with MDMA and ketanserin in various doses
to investigate the possibility whether ketanserin can block, at a
different (higher) dose, the dissociative state and the potential
glutamate increase by MDMA.
In the present study it was shown that the MDMA-
induced dissociative state related positively to one biological
measure, i.e., the effects on heart rate, but only when MDMA
was administered alone, i.e., without ketanserin. This lack of
correlation between the MDMA-induced dissociative state in the
combined ketanserin-MDMA condition and heart rate reflects
a discrepancy between effects of this pre-treatment-treatment
combination on cardiovascular versus subjective measures. It
also suggests that the heart rate per se is not directly related
to experiencing a dissociative state, since normalizing the
heart rate in the ketanserin-MDMA condition did not lead
to a reduction of dissociative state. An interesting avenue for
future research could be the inclusion of preselected high and
low cortisol responders in relation to either a psychological
or biological stressor conform previous research (Giesbrecht
et al., 2007). In this way, the effect of stress reactivity after
a stressor on dissociative state could be explored in a more
rigorous manner since the current sample size did not allow
separating groups based on cortisol response and studying this
effect.
Since MDMA is currently being explored as adjunct to
psychotherapy in post-traumatic stress disorder patients, it is
relevant to know how MDMA could augment these therapeutic
effects (Oehen et al., 2013; Mithoefer et al., 2013). Previously
is has been suggested that depersonalization leads to ‘mind-
emptiness,’ an indifference to pain, and an increased attentional
state, associated with enhanced prefrontal cortex (PFC) activation
and decreased anterior cingulate cortex activation (Sierra and
Berrios, 1998). In addition it was proposed that derealization
could lead to lowered emotionality, and lack of emotional
coloring, linked to a PFC-driven inhibition of amygdala activity
(Sierra and Berrios, 1998). Interestingly, studies have shown
that MDMA leads to increases in blood flow in prefrontal
areas and decreases in the amygdala and cingulate cortex
(Gamma et al., 2000), or alternatively to a dampened amygdala
reactivity (Bedi et al., 2009). These biological effects were
accompanied by heightened mood and increased feelings
of derealization (Gamma et al., 2000). Further research is
needed to determine whether the MDMA-induced dissociative
state is linked to this suggested indifference to pain, mind-
emptiness, and lack of emotional coloring, all cognitive-
emotional states that could help in processing traumatic
experiences.
CONCLUSION
It is suggested that the 5-HT2 receptor does not play a role
in the MDMA-induced dissociative state. Heart rate correlates
positively to this state but does not seem to be leading in
this effect. Further research is needed to determine the exact
neurobiology underlying this effect and whether these effects
contribute to the therapeutic potential of MDMA.
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